Journal
NATURE REVIEWS ENDOCRINOLOGY
Volume 13, Issue 12, Pages 697-+Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrendo.2017.136
Keywords
-
Categories
Funding
- NIH [AG004875, AG048792, AR027065]
Ask authors/readers for more resources
Romosozumab, a recently developed sclerostin inhibitor, stimulates bone formation and inhibits bone resorption, thereby markedly increasing bone mass and reducing fracture risk. But will a red flag regarding possible adverse cardiovascular events derail this promising new drug for osteoporosis?
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
